Log in to save to my catalogue

Evaluation of the England Community Pharmacy Quality Scheme (2018–2019 and 2019–2020) in reducing ha...

Evaluation of the England Community Pharmacy Quality Scheme (2018–2019 and 2019–2020) in reducing ha...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ac85d463bfa441d8b38f3c5d6ca34a91

Evaluation of the England Community Pharmacy Quality Scheme (2018–2019 and 2019–2020) in reducing harm from NSAIDs in older patients

About this item

Full title

Evaluation of the England Community Pharmacy Quality Scheme (2018–2019 and 2019–2020) in reducing harm from NSAIDs in older patients

Publisher

England: British Medical Journal Publishing Group

Journal title

BMJ open quality, 2023-01, Vol.12 (1), p.e002002

Language

English

Formats

Publication information

Publisher

England: British Medical Journal Publishing Group

More information

Scope and Contents

Contents

IntroductionNon-steroidal anti-inflammatory drugs (NSAIDs) are widely used for their analgesic and anti-inflammatory action, but the gastrointestinal (GI) adverse effects are a known cause of preventable harm. A medication safety audit was incentivised for community pharmacies in England in 2 successive years as part of the Pharmacy Quality Scheme...

Alternative Titles

Full title

Evaluation of the England Community Pharmacy Quality Scheme (2018–2019 and 2019–2020) in reducing harm from NSAIDs in older patients

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ac85d463bfa441d8b38f3c5d6ca34a91

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ac85d463bfa441d8b38f3c5d6ca34a91

Other Identifiers

ISSN

2399-6641

E-ISSN

2399-6641

DOI

10.1136/bmjoq-2022-002002

How to access this item